SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (749)3/20/2007 2:42:21 PM
From: rkrw  Read Replies (1) | Respond to of 824
 
Ian you're kind of missing the point a bit. alxn would be plenty rewarded if they charged $100-200K per year. At $200-$300K or more maybe they would be unfairly rewarded. There's plenty of room for reward without gauging imo. Keep in mind they need a tiny sales force, maybe 10-15 people, so a ton of margin is made up on on the sg&a side.



To: Ian@SI who wrote (749)3/20/2007 3:12:15 PM
From: keokalani'nui  Respond to of 824
 
Also, Solaris wasn't a "huge" risk in PNH. 'No-risk' is more like it, an 11-patient P1 proof of concept that rolled p=.000000! Furthermore, an independent UK investigator had to interest them in the idea.

Pexeli, now that was a risk.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News